|
|
Post by cannon5974 on Apr 8, 2014 13:25:13 GMT -5
clinicaltrials.gov/ct2/show/study/NCT01874392?term=animas&rank=9Anyone know how to find out when the results of this trial will be released? They were supposed to be completed in December. This intrigues me because they are using a pump from Animas, which is owned by JNJ. Obviously, JNJ would be a name you would like to hear associated with Mannkind.
|
|
|
|
Post by brentie on Apr 8, 2014 13:58:32 GMT -5
clinicaltrials.gov/ct2/show/study/NCT01874392?term=animas&rank=9Anyone know how to find out when the results of this trial will be released? They were supposed to be completed in December. This intrigues me because they are using a pump from Animas, which is owned by JNJ. Obviously, JNJ would be a name you would like to hear associated with Mannkind. So far, I think this is all we know... Keith Markey - Griffin Securities Okay. Can you tell us approximately when the data from that study will be available? Hakan Edstrom - President, Chief Operating Officer, Director I thought it would be available in just a few months, but one of the key managers at Sansum is changing his position and leaving the clinic. So I don't know what the impact of it is going to be. and I would like to take a little time to talk about some fascinating new clinical results involving AFREZZA that reinforces significance of AFREZZA's greatly improved PK/PD. This study, not previously mentioned, is in the program permitted by the Juvenile Diabetes Research Foundation. The Sansum Clinic in collaboration with the University of California Santa Barbara is conducting a study of a closed-loop "Artificial Pancreas" in which the patients inhale a dose of AFREZZA at the start of each meal. A sensor-controlled, closed-loop insulin pump then adjusts the residual glucose level 24x7 largely eliminating excessive excursions. The initial result of this study had been exceptional, glucose control was far better for those patients taking the meal-time AFREZZA dose. The resulting glucose pattern was actually very close to that for a healthy physiology. This study is continuing and the expected very positive results will be published in a few months. Indeed the obstacle with earlier efforts at close-loop glucose-controlled has been the deficient PK/PD of current prandial insulin. AFREZZA offers a potential solution to that problem for bolus control and the pump clearly offers the best solutions basal control. These efforts in UCF beats the JDRF study should therefore demonstrate that in the foreseeable future, the best glucose control in Type 1 will surely be the combination of AFREZZA plus closed loop control of the overall residual glucose level. However, complexity and especially the high cost of pumps and sensors will likely continue to be deterrent to their widespread use other than a portion of especially committed Type 1 patients. seekingalpha.com/article/1803692-mannkinds-ceo-discusses-q3-2013-results-earnings-call-transcript?find=sansum&all=falseThe significance of AFREZZA, as a more physiologic prandial insulin, was actually shown in a small study recently conducted in type 1 patients at the Sansum Clinic and supported by a grant from the Juvenile Diabetes Research Foundation. In that study, superior prandial control was achieved without any hypoglycemia when using AFREZZA for bolus dosing and closed-loop control, primarily for basal dosing. The study results showed outstanding prandial control without any hypoglycemic depressions at all. The key lesson from that study is that AFREZZA can provide outstanding physiologic prandial control as part of a basal bolus program in type 1 and late-stage type 2 patients. seekingalpha.com/article/2029531-mannkinds-ceo-discusses-q4-2013-results-earnings-call-transcript?find=sansum&all=false |
|
/production/original_573352236.gif)
